Section
Mathematical biomarkers derived from initial PSA dynamics effectively predict adaptive therapy outcomes in prostate cancer, enabling personalized treatment strategies that outperform traditional PSA measures.
This review synthesizes clinical trial evidence supporting digital patient-reported outcome monitoring with alert-based interventions to reduce fatigue and improve physical functioning in metastatic breast cancer.
Enfortumab vedotin (EV) therapy in advanced urothelial carcinoma is frequently associated with cutaneous adverse events (cAEs). These EV-induced skin toxicities correlate independently with improved progression-free and overall survival, ev
This article reviews a prospective study comparing Laser Speckle Contrast Imaging (LSCI) and Indocyanine Green (ICG) fluorescence for predicting necrosis in immediate breast reconstruction, highlighting LSCI’s repeatability and sensitivity
This study elucidates the prognostic importance of bile duct resection margin status in distal cholangiocarcinoma, revealing that margin involvement significantly affects recurrence risk in node-negative patients and identifies potential ca
A medically supervised preoperative weight loss program is feasible and leads to significant short-term weight reductions in women with obesity and atypical hyperplasia or low-grade endometrial carcinoma. Further research is necessary to co
This study explores how breast reconstruction type and device placement impact radiation therapy planning, dose distribution, treatment timing, and complications, revealing nuanced effects on heart, lung doses, and internal mammary node cov
Anti-PD-1 therapy has transformed classical Hodgkin lymphoma management, demonstrating safety, feasibility, and durable efficacy across treatment settings—from relapsed/refractory disease to frontline therapy.
BIA-ALCL is a heterogeneous T cell lymphoma marked by immunosuppressive tumor microenvironments that promote tumor survival and proliferation, revealing potential targets for advanced disease therapy.
Tumor volume regression at one year post-I-125 plaque brachytherapy significantly predicts overall survival in posterior uveal melanoma, with intermediate regression showing the best outcomes.
A study benchmarking large language models in gynecologic oncology demonstrates that guideline-anchored retrieval-augmented generation (RAG) configurations outperform baseline and literature-only AI systems in clinical decision support, hig
This study identifies key prognostic factors and proposes a graded prognostic assessment to stratify survival in patients with brain metastases from nonanaplastic follicular cell-derived thyroid carcinoma.
The I-SPY2 trial shows that combining PD-1 and LAG-3 inhibitors with neoadjuvant chemotherapy significantly improves pathologic complete response rates in early-stage high-risk ERBB2-negative breast cancer, especially in patients with a pos
This study reveals that certain high-risk cytogenetic abnormalities continue to influence progression-free survival in multiple myeloma patients even after achieving deep MRD negativity post-ASCT, highlighting the need for tailored post-tra
This review synthesizes evidence on patients’ perceptions of telehealth for head and neck cancer surveillance, highlighting barriers, benefits, and the potential of hybrid models to improve acceptability post-treatment.
Hypofractionated ablative radiation therapy after induction chemotherapy shows promise in patients with locally advanced pancreatic cancer, improving resectability and 2-year survival while maintaining acceptable safety profiles.
This study analyzes real-world data showing that MLH1 promoter hypermethylation and Lynch syndrome-associated genetic mutations confer similar response rates and survival outcomes in mismatch repair deficient endometrial cancer treated with
RIPPLY1 suppresses cancer stemness by targeting TBX19, improving prognosis in CTNNB1-mutated hepatocellular carcinoma through inhibition of tumor progression.
A novel AI model, SÉMIL, integrating vision-language and multiple instance learning, improves prognostic accuracy for stage II colorectal cancer by refining risk stratification beyond current clinical assessments, especially within NCCN hig
This retrospective study assesses the efficacy and safety of pemetrexed, alone or combined with carboplatin, as salvage therapy for advanced thyroid cancer, showing promising response rates comparable to current second-line treatments.
